SignalFDA/Bio

Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss

Subgroup benefit post-trial miss signals potential regulatory salvage path.

What changed

Subgroup benefit post-trial miss signals potential regulatory salvage path.

Why it matters

Subgroup benefit post-trial miss signals potential regulatory salvage path. — impact context not separately stored; see What changed.

Sources